Vivanza Biosciences Limited (BOM:530057)
1.770
-0.180 (-9.23%)
At close: Aug 18, 2026
Vivanza Biosciences Revenue
Vivanza Biosciences had revenue of 96.63M INR in the quarter ending June 30, 2026, with 7.88% growth. This brings the company's revenue in the last twelve months to 1.17B, up 733.83% year-over-year. In the fiscal year ending March 31, 2026, Vivanza Biosciences had annual revenue of 1.16B with 1,452.84% growth.
Revenue (ttm)
1.17B
Revenue Growth
+733.83%
P/S Ratio
0.07
Revenue / Employee
145.91M
Employees
8
Market Cap
78.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.16B | 1.09B | 1,452.84% |
| Mar 31, 2025 | 74.72M | -204.18M | -73.21% |
| Mar 31, 2024 | 278.89M | 97.35M | 53.62% |
| Mar 31, 2023 | 181.54M | 69.55M | 62.10% |
| Mar 31, 2022 | 111.99M | 12.60M | 12.67% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beryl Drugs | 215.51M |
| Fabino Enterprises | 208.41M |
| Brawn Biotech | 173.07M |
| Unjha Formulations | 152.79M |
| Decipher Labs | 138.51M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Ganga Pharmaceuticals | 28.28M |
| Emmessar Biotech & Nutrition | 23.78M |